PHILADELPHIA - So-called barrier sites -- the skin, gut, lung – limit the inner body’s exposure to allergens, pollutants, viruses, bacteria, and parasites. Understanding how the immune system works in these external surfaces has implications for understanding such inflammatory diseases as asthma, psoriasis, IBD, and food allergies, all of which occur at the body’s barriers.
David Artis, PhD, professor of Microbiology at the Perelman School of Medicine, and Gregory F. Sonnenberg, a predoctoral fellow in the Artis lab, have identified an immune cell population that acts as the body’s border patrol with the outside world. They discovered that these lymphoid tissue inducer cells maintain immunity in the intestine of mice. The research appeared in the most recent online issue of Immunity.
Following infection by Citrobacter rodentium -- a model of human E. coli infection in the gut – this cell population was the dominant source of IL-22, a molecule that helps in the immune response during the early phases of infection. When the inducer cells were eliminated from the intestine of the experimental mice, immunity was impaired, affecting the production of anti-microbial proteins required to fight infection. The mice eventually died.
This discovery could also represent a new line of research for HIV/AIDS, says Artis, since there is a breakdown of barrier immunity in the gut (a reservoir for HIV) that can lead to full blown AIDS. Therapeutics to target such immune cells could be an important new way to combat AIDS.
The research was funded by the National Institute of Allergy and Infectious Diseases, the Burroughs Welcome Fund, and the Crohn’s and Colitis Foundation of America.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.